Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346658 · ClinicalTrials.gov registry record · Phase 1
Magnesium Supplementation to Prevent Bone Loss
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00346658: Completed Phase 1 study, sponsored by University of Tennessee.
NCT00346658 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 74 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00346658, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypothesize that magnesium supplementation will have a beneficial effect on calcium regulating hormones and markers of bone turnover.
Interventions
- DRUG magnesium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 1 |
What the finished NCT00346658 record still lists
NCT00346658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 1 intervention - of which magnesium is the first listed.
NCT00346658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00346658 about?
NCT00346658 is a clinical study titled "Magnesium Supplementation to Prevent Bone Loss". Extreme magnesium deficiency is known to have an impact on the synthesis, secretion and/or action of calcium regulating hormones. Many older adults are at risk for less severe magnesium deficiency, since the majority of adults receive less than the Recommended Daily Allowance of magnesium. We hypoth...
What is the current status of trial NCT00346658?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2002-07. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00346658?
The interventions under investigation include: magnesium (DRUG).
Who is sponsoring clinical trial NCT00346658?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00346658's enrollment target sits among peer trials
74 725th of 2000 higher than 1,269 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia